- EnWave has signed a master service agreement with BioTechnique, a pharmaceutical contract manufacturing provider, to evaluate its Radiant Energy Vacuum (REV) technology.
- The collaboration will involve pilot-scale testing of liquid products at EnWave’s Innovation Center, with potential for future equipment acquisition by BioTechnique.
EnWave Corporation has entered into a master service agreement with BioTechnique, a U.S.-based pharmaceutical contract manufacturing organisation (CDMO). The agreement sets the framework for BioTechnique to assess EnWave’s Radiant Energy Vacuum (REV) dehydration technology as a potential alternative to traditional lyophilization in the biopharmaceutical sector.
The first phase of this collaboration will involve paid testing of multiple liquid pharmaceutical products. These products will be dried in vials using pilot-scale REV machinery at EnWave’s Innovation Center in Delta, British Columbia.
If the results are favourable, BioTechnique may consider acquiring its own REV equipment to integrate into its contract manufacturing services. This could allow the company to offer an alternative drying method to its pharmaceutical clients.
